News

Very Rare EGFR Mutations Respond Heterogeneously to TKIs

03/16/2022

According to the largest real-world cohort of very rare EGFR mutations in patients with NSCLC, TKIs may cause worse outcomes during treatment.

According to the largest...

03/16/2022

Oncology

News

Highly Selective Compound Gains FDA Acceptance for Next-Gen EGFR Inhibitor in NSCLC

03/08/2022

The FDA has accepted a novel IND application for clinical trials of H002, a highly selective, fourth-generation compound to treat mutation-driven resistance for NSCLC.

The FDA has accepted a novel IND...

03/08/2022

Oncology

News

Osimertinib Overcomes Asymptomatic Brain Metastases in Lung Adenocarcinoma

03/07/2022

The first prospective study of osimertinib discovers high efficacy for patients with lung adenocarcinoma who experience asymptomatic brain metastases.

The first prospective study of...

03/07/2022

Oncology

News

Circulating Tumor DNA Predictive of Tumor Response in NSCLC

03/02/2022

A sub-analysis of the FASTACT-2 trial explores if ctDNA combined with RECIST tumor assessment results in improved responses in advanced EGFR-mutant NSCLC.

A sub-analysis of the FASTACT-2...

03/02/2022

Oncology

News

ASCO Updates Guidelines for Adjuvant Systemic, Radiation Therapy for NSCLC

02/22/2022

Two randomized trials of patients with completely resected NSCLC have prompted an amendment to ASCO Guideline Recommendations for best cancer care options of adjuvant systemic therapy and adjuvant radiation therapy.

Two randomized trials of...

02/22/2022

Oncology

News

Afatinib With Anti-EGF Vaccine Inhibits Tumor Growth for Advanced NSCLC

02/10/2022

Data from the EPICAL trial confirm first line afatinib with anti-EGF vaccination inhibits tumor cell growth, induces a sustained immunogenic effect in patients with advanced NSCLC.

Data from the EPICAL trial...

02/10/2022

Oncology

News

Ivonescimab Projected to Treat EGFR-TKI Resistant, Advanced NSCLC

02/04/2022

A phase 3 trial projects substantial antitumor effect with ivonescimab in patients with EGFR-TKI resistant, advanced, or metastatic NSCLC with an EGFR mutation.

A phase 3 trial projects...

02/04/2022

Oncology

News

Dr Yu Shares Updates of Prevention Efforts in EGFR-Mutant Lung Cancer

10/05/2021

Helena Yu, MD, discusses updates of small cell histologic transformation in EGFR-mutant lung cancers at the virtual 2021 Personalized Therapies in Thoracic Oncology meeting.

Helena Yu, MD, discusses updates...

10/05/2021

Oncology

News

Dr Yu Shares Updates of Prevention Efforts in EGFR-Mutant Lung Cancer

10/05/2021

Helena Yu, MD, discusses updates of small cell histologic transformation in EGFR-mutant lung cancers at the virtual 2021 Personalized Therapies in Thoracic Oncology meeting.

Helena Yu, MD, discusses updates...

10/05/2021

Oncology

Conference Coverage

Treatment Courses for Third Generation EGFR TKI Resistance in Lung Cancer

10/02/2021

At the virtual 2021 Personalized Therapies in Thoracic Oncology meeting Lyudmila Bazhenova, MD provided an overview of how to manage lung cancer patients with TKI-resistance.

At the virtual 2021 Personalized...

10/02/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology